As of Dec 13
| -0.84 / -0.77%|
The 29 analysts offering 12-month price forecasts for Celgene have a median target of 125.00, with a high estimate of 166.00 and a low estimate of 91.00. The median estimate represents a +15.53% increase from the last price of 108.20.
The current consensus among 34 polled investment analysts is to Buy stock in Celgene. This rating has held steady since December, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.